Concepedia

Matthias Bräutigam

MB

67

Publications

3.6K

Citations

37

H-Index

1982

Active since

Affiliations

Novartis (Germany)(Current)

Novartis (Switzerland)

Charité - Universitätsmedizin Berlin

University of Münster

Christian-Albrechts-Universität zu Kiel

Matthias Bräutigam is an author at Novartis (Germany) specializing in medicine, dermatology, and pharmacology.

Top concepts

Publications per year

1982–2017

67

Publications

67

Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase

Marcus Maurer, Sabine Altrichter, Thomas Bieber et al. · Journal of Allergy and Clinical Immunology · 2011 · 354 citations

, , +8

Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Adults: A Six-Month Study

Michael J. Meurer, Regina Fölster‐Holst, Gottfried Wozel et al. · Dermatology · 2002 · 220 citations · Full text

Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis

Jens‐Michael Jensen, Stephan Pfeiffer, Magdalena Witt et al. · Journal of Allergy and Clinical Immunology · 2009 · 165 citations

, , +9

Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection

Matthias Bräutigam, Siegfried Nolting, R.E. Schopf et al. · BMJ · 1995 · 144 citations · Full text

Effect of omalizumab on angioedema in H <sub>1</sub> ‐antihistamine‐resistant chronic spontaneous urticaria patients: results from X‐ <scp>ACT</scp> , a randomized controlled trial

Petra Staubach, Martin Metz, Nadine Chapman‐Rothe et al. · Allergy · 2016 · 128 citations

Rows per page

1–5 of 67